Pages,Columns,Lines where

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10596828			
Filing Date		2006-06-26			
First Named Inventor Touto		mu Ishihara			
Art Unit		1615			
Examiner Name	to be	assigned			
Attorney Docket Number		KPO-LTT-P5/LTT-98/US			

Examiner Initial*	r Cite No Patent Number		Kind Code ¹			Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	5091188		1992-02	2-25	Duncan Hayn	es				
	2	6097324		2000-07	7-11	Yasutaka Igar	i				
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add		_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name or Patentee or Applicant Releva		s,Columns,Lines where ant Passages or Relevant as Appear			
	1	20040081688		2004-04-29		Maria Dorty Del Curto					
	2	20040185113		2004-01	J-23	Yutaka Mizusi	hima				
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Ad	d button	Add		_
				FOREI	GN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²			Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rel	or Relevant	Ts
	1	2003-081865	JP			2003-03-19	Kimura Michio				Ī

U.S. PATENTS

| Application Number | 100998278 | Filing Date | 2006-96-28 | Filing Date |

	2	WO 99/43426	wo		1999-09-02	Philippe Grisoni			
	3	EP 1 342471 B1	EP		2003-04-02	Jean-Thierry Simonnet			
	4	WO 00/67800	wo		2000-11-16	Rainer Muller			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	Add		
			NON-PATER	NT LITE	ERATURE DO	CUMENTS	Remove		
Examiner Initials*	Examiner Cite initials* Colon, and control of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item initials* Colon, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ţ5		
	MITSUKO TAKENAGA, "A novel sustained-release formulation of insulin with charmatic reduction in initial rapid release", Journal of Controlled Release, vol. 79, p. 81-91 (2002), Elsewer, Japan								
	2 *Clinical Pharmacology*, Jpn. J. Clin. Pharmacol. Ther., vol. 26(1), p. 127-128 (1995), Japan								
	3	*DRUG DELIVERY SYS (1999), Japan	TEM Today's DDS	S drug d	elivery system*,	Iyaku Medicine and Drug Jo	ournal, p. 325-33	31	
	4 SADASUKE OKANO, "Shin Yakuzaigaku Soron", New General Statement of Pharmaceudos, Revision 3, p. 65-66 (Agril 10, 1997), Nankodo Co., Japan VOKO YAMAGUCHI, et al., "All-trans Relinoic Acid (ATRA) CaCO3 Nano-particle no Johosei no Kento", Lecture Summary of Seventeenth Annual Meeting of Academy of Pharmaceutical Science and Technology, p. 88, (March 27, 2002), Japan							-66	
	6	AKIRA YAMAMOTO, "In Zasshi, vol. 121, p. 929-			isal Absorption o	f Biologically Active Peptide	Drugs", Yakuga	aku	
If you wis	h to a	d additional non-paten	t literature docu	ment ci	tation informati	on please click the Add b	outton Add		_

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10596828			
	Filing Date			2006-06-26		
	First Named Inventor Tsutor		mu Ishihara			
	Art Unit		1615			
	Examiner Name	to be	assigned			
	Attorney Docket Number		KPO-LTT-P5/LTT-98/US			

	EXAMINER SIGNATURE					
Examiner Signature		Date Considered				
EVALUATED IN A 12 of the second of the secon						

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kinz Codes of USPTO Patent Documents at www.USPTO_GOV or MPEP 901.04. ² Enter office that issued the document, by the how-lefter code (WIPO Standard ST.3). ² Sort Japances patent obcuments, by making on the year of the Proprior must procect the serial number of the patent document.

*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ³ Applicant is to place a check mark here if English tanguage the instantation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10596828
Filing Date		2006-06-26
First Named Inventor Tsutor		mu Ishihara
Art Unit		1615
Examiner Name	to be	assigned
Attorney Docket Number		KPO-LTT-P5/LTT-98/US

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 t	o make the	appropriate selection(s):
---------------	----------	------------	------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/manette dennis/	Date (YYYY-MM-DD)	2007-02-16
Name/Print	Manette Dennis	Registration Number	30.623

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bs 1449, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.